Bo Lennernäs

Bo Lennernäs is a Swedish life science company and research entity founded by Dr. Bo Lennernäs, a prominent oncologist and associate professor at Uppsala University. The company serves as the primary vehicle for Dr. Lennernäs's innovations in drug delivery, most notably the NanoZolid technology, which enables the controlled, local release of therapeutic agents. This technology was the foundation for the establishment of LIDDS AB, where Dr. Lennernäs is a co-founder and has overseen the development of Liproca Depot for the treatment of prostate cancer. Additionally, the company's research contributed to the development of BupiZenge, a novel formulation for oral mucositis pain, currently being advanced by OncoZenge AB. Bo Lennernäs remains active in clinical research and provides strategic consulting services to the pharmaceutical and biotechnology sectors.